Tierney JF et al. Evidence synthesis to accelerate and improve the evaluation of therapies for metastatic hormone-sensitive prostate cancer. European Urology Focus, 2019; Jan 31. pii: S2405-4569(19)30005-7. doi: 10.1016/j.euf.2019.01.005
Burdett S et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. European Urology, 2019; doi: 10.1016/j.eururo.2019.02.003
Vale CL et al. What is the optimal systemic treatment for men with metastatic, hormone- naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals of Oncology, 2018; 29(5): 1249-1257.
Rydzewska LHM et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. European Journal of Cancer, 2017; 84: 88-101.
Vale CL and Burdett S et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncology, 2016;17(2): 243-256.